SWINE FLU AWARENESS BY Dr. Mohit Bhutani Dr. D. Himanshu M.D.

SWINE FLU AWARENESS

BY

Dr. Mohit Bhutani

Dr. D. Himanshu M.D

Influenza pandemics & emerging new pandemic threats exist since 1900!

The emergence of H1N1 has demonstrated the difficulty in predicting pandemics

Nicholson KG, Wood JM, Zambon M. Lancet 2003; 362:1733-1745; WHO, Cumulative number of confirmed human cases of avian influenza A/(H5N1), available at: http://www.who.int/csr/disease/avian_influenza/country/cases_table_2008_09_10/en/index.html (accessed 5 November 2008); CDC, Avian Influenza, available at: http://www.cdc.gov/flu/avian/outbreak.htm (accessed 5 November 2008).

Pandemic outbreaks Recent outbreaks of influenza

1918 1957 1977 2000 2008

>50 million deaths

H1N1

1918Spanish

1957Asian

~2 million deaths

H2N2

1968Hong Kong

~1 million deaths

H3N2

<1 million deaths

H1N1

1977Russian

H9N2

1999Hong Kong

2 cases

H5N1

1997Hong Kong

18 cases

Six

deaths

H7N7

82 cases

One death

H5N1

2003-2008

Global

387 cases

245 deaths

2003Dutch

1968

H1N1

2009Global

~30,000 cases

145 deaths

2009

Pandemic

http://www.who.int/csr/disease/avian_influenza/country/cases_table_2008_09_10/en/index.html

http://www.cdc.gov/flu/avian/outbreak.htm

The guiding principles are:* Early implementation of infection control precautions to minimize nosocomical / household spread of disease

Prompt treatment to prevent severe illness & death.

Early identification and follow up of persons at risk.

*Pandemic Influenza A H1N1 Clinical management Protocol and Infection Control Guidelines Directorate

Infrastructure / manpower / material support *

Isolation facilities: if dedicated isolation room is not available

then patients can be cohorted in a well ventilated isolation ward

with beds kept one meter apart.

Manpower: Dedicated doctors, nurses, paramedical workers.

Equipment: Portable X Ray machine, ventilators, large oxygen

cylinders, pulse oxymeters

Supplies: Adequate quantities of Personal Protection Equipments

(PPE), disinfectants and medications (Oseltamivir, antibiotics and

other medicines)


Standard Operating Procedures *

Reinforce standard infection control precautions

oall those entering the room must use high efficiency N95

masks, gowns, goggles, gloves, cap and shoe cover.

Restrict number of visitors and provide them with PPE.

Provide antiviral prophylaxis to health care personnel

managing the case and ask them to monitor their own health

twice a day.

Dispose waste properly by placing it in sealed impermeable

bags labeled as Bio- Hazard


MANAGEMENT

The first thing is to differentiate between a flu and a cold

CATEGORISATION OF CASES*

MILD OR UNCOMPLICATED ILLNESS

PROGRESSIVE ILLNESS

SEVERE OR COMPLICATED ILLNESS

*Updated Interim Recommendations for the Use of Antiviral Medications in the Treatment and Prevention of Influenza for the 2009-2010 Season

Mild or Uncomplicated illness

– Fever

– Cough

– Sore throat

– Rhinorrhea

– Muscle pain

– Headache

– Chills

– Malaise

– Diarrhea and vomiting

• These patients do not require treatment with anti-viral

drugs as they do not need hospitalization.

TREATMENT ALGORITHM FOR MILD DISEASE

HIGH RISK GROUP*

Children younger than 2 years old

Adults 65 years of age or older

Pregnant women and women up to 2 weeks postpartum (regardless

of how the pregnancy ended)

Persons with certain medical conditions: asthma, chronic lung

disease, heart disease, blood disorders, kidney and liver disease,

diabetes mellitus, immunocompromised and obese


Progressive illness

Typical symptoms plus

– Chest pain

– Tachypnea i.e. respiratory rate > 30

– Hypoxia i.e. SpO2 < 94% at room air

– Labored breathing in children

– Low blood pressure i.e. SBP < 90mmHg

– Confusion

– Severe dehydration

– Exacerbations of chronic conditions

These patients require urgent hospitalization and treatment.

Severe or Complicated Illness• Abnormal CXR

• Requiring mechanical ventilation

• Encephalitis

• Encephalopathy

• Organ failure

• Myocarditis

• Rhabdomyolysis

• Invasive secondary bacterial infection based on laboratory testing

or clinical signs (e.g. persistent high fever and other symptoms

beyond three days)

These patients require prompt admission and treatment with anti-viral drugs.

Whom to test The following people should receive influenza diagnostic testing

– people who are hospitalized with suspected flu i.e. patients with

progressive or severe/complicated disease

– Symptomatic patients in high risk group

– Additional people may be recommended for testing based on the clinical

judgment of their health care provider

• During 2009 H1N1 CDC considered that most people with flu symptoms

would not require testing because the test results usually do not change the

way one is treated.


How to treat !!!

• Antiviral drugs: oseltamivir (oral), zanamivir (inhaled)

• Initiate treatment as early as possible after onset of symptoms

• Treat empirically before diagnostic test results are reported


• OSELTAMIVIR : oral (cap/suspension) Oseltamivir is the recommended drug both for

prophylaxis and treatment. Neuraminidase inhibitor Pregnancy category ‘c’

SCHEDULE

ADVERSE EFFECTS(oseltamivir)

• >10%- gastrointestinal- vomiting, nausea , pain

abdomen

• 1%- conjuctivitis

• 1%- epistaxis

• <1%- anaphylactic reaction,

pseudomembranous colitis, SJS/TEN, abnormal

LFT, neuropsychiatric events

• Zanamivir – inhalational .(Relenza®) FDA-approved for the treatment of influenza in patients

7 years of age and older Caution

Bronchospasm in asthma patients

SINGLE DOSE Peramivir A third neuraminidase inhibitor formulated for intravenous (IV)

administration for 18yrs and older pt.

• Treatment approved only if:

(1) the patient has not responded to either oral or inhaled antiviral therapy;

(2) drug delivery by a route other than IV is not expected to be dependable or is not feasible

http://www.cdc.gov/h1n1flu/eua/peramivir.htm

http://www.cdc.gov/h1n1flu/eua/peramivir.htm

• AMANTADINE• RIMANATADINE

Not recommended due to widespread resistance in 2009 H1N1 strain

Duration of antiviral therapy*

Recommended duration: 5 days Hospitalized patients with severe infections might require

longer treatment courses Treatment is most effective when started in the first 48 hours

of illness Limited data from observational studies suggests, treatment

started 48 hours after onset of illness also reduced mortality/ duration of hospitalization


Supportive therapy

• IV Fluids.

• Oxygen therapy/ ventilatory support

• Antibiotics for secondary infection

• Vasopressors for shock

• Paracetamol or ibuprofen for fever, myalgia and headache.

• Avoid smoking.

• For sore throat, short course of topical decongestants, saline nasal

drops, throat lozenges and steam inhalation.

• Salicylate / aspirin is strictly contra-indicated in any influenza patient

due to its potential to cause Reye’s syndrome.

Discharge Policy • Patients responded within 2-3 days can be discharged

after 5 days of treatment. No need for a repeat test.

• Patients who continue to have symptoms of fever, sore

throat etc. even on the 5th day should continue

treatment for 5 more days.

• If symptomatic even after 10th day of treatment in the

absence of secondary infection, retest

• If positive, do check for resistance

• While discharging, educate family on personal

hygiene and infection control measures at home

ACTIVE PREVENTION

Antiviral Chemoprophylaxis of exposed individuals

INFECTIOUS PERIOD

One day before fever begins until 24 hours after fever ends or 7 days after onset of symptoms.

Children may spread the virus for a longer period

Mode of exposure• Droplet exposure of mucosal surfaces (e.g. nose, mouth, and

eyes) by respiratory secretions from coughing or sneezing • Contact, usually of hands, with an infectious patient or fomites

followed by self-inoculation of virus onto mucosal surfaces such as those of the nose, mouth, and eyes

• Small particle aerosols in the vicinity of the infectious individual.

Who may be considered for antiviral chemoprophylaxis

• The following persons who are a close contact of a person with suspected or confirmed H1N1 influenza during the infectious period:– Persons at high risk for complications of influenza;– Health care workers and emergency medical personnel;– Pregnant women.

Whom not to treat chemoprophylactically• Groups of healthy children or adults based on potential

exposures in the community, workplace, school, camp or other settings;

• If >48 hours have elapsed since the last close contact• The close contact did not occur during the infectious period

Oseltamivir AND Zanamivir drug of choice

• Prophylaxis should be provided till 10 days after last exposure

Use of the Pandemic (H1N1) 2009 vaccines

1. Inactivated – killed• Produced by growing virus in chicken eggs• Given by injection into the upper arm. In infants and

younger children the thigh is the preferred site for the vaccine shot.

TYPES: • Trivalent VAXIGRIP (flu shot: A/H1N1, A/H3N2, and B) • 50-80% protection• Can be given in pregnancy• Single dose in adults• Immunosuppressed and in children < 10 yr two doses 4 wks

apart• S/E: fever ; GBS 1 in 1 lac . C/I – ALLERGIC pts.

2.LIVE ATTENUATED • administered by nasal spray.• healthy individuals 2-49 yr of age• Contraindicated in

– pregnancy– immunosuppresed

• 90% protection rate• Not advised for health care professionals

Influenza vaccines only become effective about 14 days after vaccination

Who will receive priority for vaccination?

• WHO recommend that health workers be given first priority for early vaccination to protect themselves and their patients

• Those caring for high risk individuals who cannot receive vaccination

• Other groups at higher risk for severe illnesso pregnant womeno aged above 6 months with one of several chronic medical

conditions, o healthy adults of 65 years of age and above

PASSIVE PREVENTION

Guidelines on Infection control Measures

• FOR HEALTH CARE INDIVIDUALS

Personal Protection Equipments reduces the risk of infection if

used correctly

• Gloves (nonsterile),

• Mask (high-efficiency mask) / Three layered surgical mask,

• Long-sleeved cuffed gown,

• Protective eyewear (goggles/visors/face shields),

• Cap (may be used in high risk situations where there may be increased

aerosols),

• Plastic apron if splashing of blood, body fluids, excretions and secretions is

anticipated

N95 Respirator

• Filters 95% of airborne particulates

*NIOSH- National Institute for Occupational Safety and Health. Agency under CDC.

During Hospital Care

o The patient should be admitted directly to the isolation

facility and continue to wear a three layer surgical mask

O The identified medical, nursing and paramedical

personnel attending the suspect/ probable / confirmed

case should wear full complement of PPE .

o If splashing with blood or other body fluids is anticipated,

a water proof apron should be worn over the PPE

• Perform hand hygiene before and after patient contact and following contact with contaminated items, whether or not gloves are worn. Hand washing and Hand rub

• The virus is inactivated by

– 70% ethanol,

– 5% benzalkonium chloride (Lysol) and 10% sodium hypochlorite.

• Patient rooms/areas should be cleaned at least daily and finally

after discharge of patient. To avoid possible aerosolization of

the virus, damp sweeping should be performed.

• Recommended bed to bed distance should be at least 1m

• All waste generated from influenza patients is infectious

clinical waste and should be treated and disposed in

accordance with national regulations.

FOR GENERAL POPULATION IN COMMUNITY

• Wash hands frequently with soap and water. If soap and water are

not available, use an alcohol-based hand rub

• Cover your mouth and nose with a tissue when coughing or sneezing

• Avoid touching your eyes, nose and mouth

• People who are sick with an influenza-like illness should stay home

for at least 24 hours after fever is gone except to get medical care or

for other necessities

• Avoid close contact (i.e. being within about 6 feet) with persons with

Influenza like illness

Guidelines on Infection control Measures

THANK YOU

SWINE FLU AWARENESS BY Dr. Mohit Bhutani Dr. D. Himanshu M.D.

Documents

Transcript of SWINE FLU AWARENESS BY Dr. Mohit Bhutani Dr. D. Himanshu M.D.